ClinicalTrials.gg
Active, not recruitingNCT04657289Updated Oct 29, 2026

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

A Phase 3 interventional study of Ranibizumab and Port Delivery System with Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche. Active, not recruiting at 104 sites in 16 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
16th of 124
451 · median 64
Started
2021
with 3 others
Phase 3
31 of 125
2 open now
Registered
115th of 125
by date
Lead sponsor
5 of 125
Hoffmann-La Roche

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 16th largest by enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 in phase 3, and was the 115th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

03

Conditions studied

  • Neovascular Age-related Macular Degeneration (nAMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 50 years at time of signing Form
  • Initial diagnosis of nAMD within 9 months prior to the screening visit
  • Previous treatment with at least three anti- vascular endothelial growth factor (VEGF) intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit
  • Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis
  • Availability of historical visual acuity data prior to the first anti-VEGF treatment for nAMD until the time of study enrollment
  • BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better

Exclusion criteria

Exclusion Criteria:

  • History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye
  • Prior treatment with Visudyne®, external-beam radiation therapy, or transpupillary thermotherapy in study eye
  • Previous treatment with intravitreal injection, intraocular device implantation, previous laser (any type) used for AMD treatment in study eye
  • Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the enrollment visit in study eye
  • Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant
  • Prior treatment with brolucizumab (at any time prior to the screening visit) in either eye
  • Prior participation in a clinical trial involving any anti-VEGF drugs, within 9 months prior to the enrollment visit in either eye
  • Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is >0.5 disc area at screening in study eye
  • Subfoveal fibrosis or subfoveal atrophy in study eye
  • Choroidal neovascularization (CNV) due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia in either eye
  • Retinal pigment epithelial tear in study eye
  • Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results in study eye
  • Active intraocular inflammation in study eye
  • History of vitreous hemorrhage in study eye
  • History of rhegmatogenous retinal detachment in study eye
  • History of retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit in study eye
  • History of pars plana vitrectomy surgery
  • Aphakia or absence of the posterior capsule in study eye
  • Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia in study eye
  • Preoperative refractive error that exceeded 8 diopters of myopia, for Participants who have undergone prior refractive or cataract surgery in study eye
  • Intraocular surgery within 3 months preceding the enrollment visit in study eye
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a participant's participation in the study in study eye
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery in study eye
  • History of corneal transplant in study eye
  • Any history of uveitis requiring treatment in either eye
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
  • Uncontrolled blood pressure
  • History of stroke within the last 3 months prior to
  • Atrial fibrillation diagnosed or worsened within the last 3 months prior to informed consent
  • History of myocardial infarction within the last 3 months prior to informed consent,
  • History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or renders the participant at high risk of treatment complications in the opinion of the investigator
  • Confirmed active systemic infection
  • Use of any systemic anti-VEGF agents
  • Active cancer within 12 months of enrollment except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of \<= 6 and a stable prostate-specific antigen for > 12 months
  • Previous participation in any non-ocular disease studies of drugs within 1 month preceding the informed consent
  • Non-functioning non-study eye
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    Arm A [Q36W] 36-weeks between refill-exchange procedures

    Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.

    Drug: Ranibizumab · Device: Port Delivery System with Ranibizumab

  • Active comparator
    Arm B [Q24W] 24-weeks between refill-exchange procedures

    Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.

    Drug: Ranibizumab · Device: Port Delivery System with Ranibizumab

Interventions

  • Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

  • DevicePort Delivery System with Ranibizumab

    Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals

06

What researchers measure

Primary outcomes

  1. Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 meters

    EDTRS = Early Treatment Diabetic Retinopathy Study. A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.

    Time frame: Baseline to Week 72

Secondary outcomes

  1. Change from baseline in BCVA score over time

    Time frame: Baseline up to Week 72

  2. Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better averaged over Weeks 68 and 72

    Time frame: Baseline to Week 72

  3. Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better over time

    Time frame: Baseline up to Week 72

  4. Percentage of participants with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse averaged over Weeks 68 and 72

    Time frame: Baseline to Week 72

  5. Percentage of participants with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse over time

    Time frame: Baseline up to Week 72

  6. Percentage of participants who report preferring ranibizumab 100 mg/mL delivered via the PDS compared with intravitreal treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at At Weeks 24, 40 and 72

    Time frame: At Weeks 24, 40, 72

  7. Percentage of participants with bilateral disease who report preferring ranibizumab 100 mg/mL delivered via the PDS compared with intravitreal treatment, as measured by the PPPQ at At Weeks 24, 40 and 72

    Time frame: At Weeks 24, 40, 72

  8. Mean overall treatment satisfaction at Week 40, as measured by the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) total score in the Q36W arm compared with the Q24W arm

    Time frame: At Week 40

  9. Percentage of participants who lose <10, <5, or gain >= 0 letters in BCVA score from baseline averaged over Weeks 68 and 72

    Time frame: Baseline to Week 72

  10. Percentage of participants who lose <10, <5, or gain >= 0 letters in BCVA score from baseline over time

    Time frame: Baseline up to Week 72

  11. Incidence and severity of ocular and systemic (non-ocular) adverse events in the Q36W and Q24W arms

    Time frame: Baseline up to Week 72

  12. Incidence, severity, and duration of adverse events of special interest, including ocular adverse events of special interest in the Q36W and Q24W arms

    Time frame: Baseline up to Week 72

  13. Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 days of initial implantation) and follow-up period (> 37 days after implantation surgery) in all enrolled participants

    Time frame: Baseline up to Week 72

  14. Incidence and severity of adverse device effects in the Q36W and Q24W arms

    Time frame: Baseline up to Week 72

  15. Incidence, causality, severity, and duration of anticipated serious adverse device effects in the Q36W and Q24W arms

    Time frame: Baseline up to Week 72

  16. Change from baseline in center point thickness (CPT) up to and including Week 72

    Time frame: Baseline up to Week 72

  17. Percentage of participants who do not undergo supplemental treatment with intravitreal ranibizumab 0.5 mg before each refill-exchange procedure

    Time frame: Week 16 to Week 68

  18. Observed serum concentration of ranibizumab at specified timepoints

    Time frame: Baseline to Week 72

  19. Incidence of treatment-emergent ADAs during the study

    Time frame: Baseline to Week 72

07

Study locations

104 sites

Showing the first 100 of 104 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Feb 2027, 66 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 66 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
Jul 14, 2021
Primary completionEst.
Feb 4, 2027
CompletionEst.
Feb 4, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04657289
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Jul 14, 2021
Primary completion
Feb 4, 2027 (estimated)
Completion
Feb 4, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion